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Abbreviations
 BAP1   BRCA1-associated protein 1
 CCL2  Chemokine (C-C motif) ligand 2 (Monocyte 
chemoattractant protein-1)
 CCL3   Chemokine (C-C motif) ligand 3 (Macrophage 
inflammatory protein 1α)
 CCL5   Chemokine (C-C motif) ligand 5 (RANTES)
 CXCL10   Chemokine (C-X-C motif) ligand 10 (Inter-
feron gamma-induced protein 10)
 CXCL12   Chemokine (C-X-C motif) ligand 12 (Stromal 
cell-derived factor 1)
 dPCR   Digital polymerase chain reaction
HLA  Human leukocyte antigen
 IF   Immunofluorescence
 IHC   Immunohistochemistry
 NF-κB   Nuclear factor κB
 SNP  Single-nucleotide polymorphism
TCGA  The Cancer Genome Atlas
UCH  Ubiquitin-carboxy-terminal hydrolase
UCHL1  Ubiquitin carboxyl-terminal hydrolase L1
UCHL2  Ubiquitin carboxyl-terminal hydrolase L2
 UM   Uveal melanoma
 VEGFA   Vascular Endothelial Growth Factor A
Introduction
Uveal melanoma (UM) is the most common primary 
intraocular malignancy in Caucasian adults and may lead 
to metastatic disease in up to 50% of patients [1, 2]. Cur-
rent treatments are hardly ever effective against metastases 
[3], and hence, most research efforts are focused on the 
Abstract Uveal melanoma (UM) is characterized by a 
number of genetic aberrations that follow a certain chronol-
ogy and are tightly linked to tumor recurrence and survival. 
Loss of chromosome 3, bi-allelic loss of BAP1 expression, 
and gain in chromosome 8q have been associated with 
metastasis formation and death, while loss of chromosome 
3 has been associated with the influx of macrophages and 
T cells. We used a set of genetically-classified UM to study 
immune infiltration in the context of their genetic evolu-
tion. We show in two independent cohorts that lack of 
BAP1 expression is associated with an increased density of 
 CD3+ T cells and  CD8+ T cells. The presence of extra cop-
ies of chromosome 8q in disomy 3 tumors with a normal 
BAP1 expression is associated with an increased influx of 
macrophages (but not T cells). Therefore, we propose that 
the genetic evolution of UM is associated with changes in 
the inflammatory phenotype. Early changes resulting in 
gain of chromosome 8q may activate macrophage infiltra-
tion, while sequential loss of BAP1 expression seems to 
drive T cell infiltration in UM.
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development of targeted therapies or immunotherapeutic 
approaches, such as treatments with immune checkpoint 
inhibitors, vaccination, or adoptive T cell therapy [4–8].
Some UM express increased levels of human leukocyte 
antigen (HLA) class I and are infiltrated by macrophages 
and lymphocytes, and this is known as an inflammatory 
phenotype [9–12]. The presence of this inflammatory phe-
notype has been correlated with a specific genetic aber-
ration, which is the loss of one copy of chromosome 3 
(monosomy 3) [13]. Other chromosomal abnormalities fre-
quently occur in chromosomes 1, 6, and 8 [14–17]. Follow-
ing an initiating mutation in either GNAQ or GNA11, gain 
of 8q is thought to be one of the earliest genetic aberrations, 
followed by loss of one chromosome 3 [18, 19]. Gain of 8q 
and monosomy 3 and are both associated with the devel-
opment of UM metastases and a poor prognosis [16, 20]. 
Similarly, gene expression analysis has been used to divide 
UM into two major classes, 1 and 2, which are good predic-
tors of prognosis [21, 22]. Moreover, we recently showed 
that, in our hands, class II tumors can be subdivided into 
IIa and IIb: while class IIa tumors are composed of highly 
homogeneous tumor cells and class IIb tumors contain a 
larger percentage of non-tumor cells which are likely to be 
immune cells. Interestingly, class IIa and IIb tumors dif-
fered in their numbers of chromosome 8q copies [19].
Chromosome 3 contains the gene for BRCA1-associated 
protein 1 (BAP1). In UM, inactivating hemizygous muta-
tions in this gene have been found [23, 24], which are asso-
ciated with loss of BAP1 protein expression and a high 
metastatic risk [23–26]. However, monosomy 3 and loss 
of BAP1 may occur independently, as tumors with a nor-
mal chromosome 3 status with lack of BAP1 expression 
have been identified, as well as tumors with monosomy 3 
that still express BAP1. Such atypical tumors show high-
risk clinico-pathological features and convey an increased 
metastatic risk [25]. BAP1 is a member of the ubiquitin-
carboxy-terminal hydrolase (UCH) family [27], and is 
also known as ubiquitin carboxyl-terminal hydrolase L2 
(UCHL2). Another member of the UCH family, ubiqui-
tin carboxyl-terminal hydrolase L1 (UCHL1), is associ-
ated with suppressed production of pro-inflammatory 
chemokines and cytokines in keratinocytes [28]. We, there-
fore, hypothesized that loss of BAP1 expression might be 
related to macrophage and/or T cell infiltration.
To assess whether genetic alterations affect immune 
cell infiltration in UM, we studied the presence and type of 
tumor-infiltrating immune cells in UM subtypes consisting 
of typical cases of UM (e.g. disomy 3 tumors with BAP1 
expression and monosomy 3 with loss of BAP1 expression) 
and atypical cases of UM (e.g. disomy 3 tumors with loss of 
BAP1 expression and monosomy 3 tumors with expression 
of BAP1). In addition, we studied disomy 3/BAP1-positive 
cases with and without extra copies of chromosome 8q.
Our data show that loss of BAP1 protein expression is 
predominantly related to T cell infiltration in UM, while 
early gain of chromosome 8q is associated with mac-
rophage infiltration.
Materials and methods
Patient selection
Tumor tissue specimens were obtained from 84 UM 
patients. Patients underwent primary enucleation for UM 
between 1999 and 2008 at the Leiden University Medical 
Center (Leiden, The Netherlands). Part of the tumor was 
snap frozen using 2-methyl butane, and DNA and RNA 
were isolated. The remaining tumor was fixed in 4% neu-
tral-buffered formalin for 48 h and subsequently embedded 
in paraffin. This study was approved by the Medical Eth-
ics Committee of the Leiden University Medical Center. 
Tumor material was handled according to the Dutch 
National Ethical Guidelines (‘Code for Proper Secondary 
Use of Human Tissue’), and the tenets of the Declaration 
of Helsinki (World Medical Association of Declaration 
2013; ethical principles for medical research involving 
human subjects). In addition, 80 patients from The Cancer 
Genome Atlas (TCGA) Project on UM were included in 
this study as an independent validation cohort.
Immunohistochemistry and fluorescent 
immunostaining of the Leiden Cohort
4-µm serial sections from paraffin-embedded tissue were 
cut and used for immunostaining. Immunohistochemistry 
(IHC) of BAP1 was performed on 74 tumors, as described 
previously [24]. Tumors were scored by two independ-
ent investigators as BAP1-positive or -negative based on 
nuclear staining. Immunofluorescence (IF) staining for 
T cells and macrophages was performed on 43 tumors as 
described previously [29, 30]. T cell types were detected 
by primary antibodies: anti-CD3 (ab828, rabbit polyclonal; 
Abcam, Cambridge, MA, United States of America) and 
anti-CD8 (4B11, mouse monoclonal IgG2b; Novocastra, 
Valkenswaard, The Netherlands). To visualize the T cells, 
the following secondary antibodies were used: goat-anti-
rabbit IgG Alexa 546 and goat-anti-mouse IgG2b Alexa 
647 (Molecular Probes, Invitrogen, Breda, The Nether-
lands). Counts of intratumoral  CD3+ and  CD8+ T cells 
were represented as the number of cells per square mil-
limeter. For IF staining of  CD68+ macrophages, we used 
the primary mouse anti-human macrophage CD68 anti-
body (clone 514H12; ab49777; Abcam, Cambridge, United 
Kingdom), and as secondary antibody AlexaFluor IgG2a 
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(488) goat-anti-mouse. The amount of  CD68+ expression 
was determined in pixels per square millimeter.
DNA and gene expression analysis
DNA and gene expression analysis were performed on 54 
tumor specimens from Leiden, in which the BAP1 status 
was known. The QIAmp DNA Mini kit was used to isolate 
DNA for single-nucleotide polymorphism (SNP) analysis 
(Qiagen, Venlo, The Netherlands). SNP analysis was then 
performed with the Affymetrix 250K_NSP microarray and 
Affymetrix Cytoscan HD chip (Affymetrix, Santa Clara, 
California, United States of America) to detect aberrations 
of chromosome 3 as described previously [20]. Informa-
tion on chromosome 8q was obtained by digital polymer-
ase chain reaction (dPCR) [20]. A threshold of >2.1 was 
defined as having extra copies of chromosome 8q. The 
RNeasy mini kit was used to isolate RNA for gene expres-
sion analyses (Qiagen, Venlo, The Netherlands). Gene 
expression levels of CD3 and CD8 (T cells), CD68 (mac-
rophages), and pro-inflammatory cytokines, specifically 
macrophage inflammatory protein 1α (CCL3), vascular 
endothelial growth factor A (VEGFA), stromal cell-derived 
factor 1 (CXCL12), CCL7, CSF-1, monocyte chemoat-
tractant protein-1 (CCL2), RANTES (CCL5), interferon 
gamma-induced protein 10 (CXCL10), CCR7, and CXCR4 
were obtained using the Illumina HT-12 v4 chip (Illumina, 
San Diego, California, United States of America). The pro-
inflammatory cytokines were selected based on our previ-
ous papers [31–33]. We could validate the probes for CD3, 
CD8 and CD68 in 24 tumors in which gene expression lev-
els had been determined with an Illumina HT12 v4 array 
and in which the number of infiltrating cells was analyzed 
by IF. In addition, data on RNA sequencing and Affyme-
trix SNP 6.0 array from 80 samples of UM were obtained 
from the TCGA Research Network: http://cancergenome.
nih.gov/. Copy numbers for 8q were determined by Affy-
metrix SNP 6.0 array and analyzed with the GISTIC 2.0 
algorithm [34, 35]. Copy numbers >2 were categorized as 
extra copies of chromosome 8q. BAP1, CD68, CD3, and 
CD8 expression were obtained by RNA sequencing  and 
quantified as log2(RSEM+1). BAP1 expression was dichot-
omized into BAP1-positive and BAP1-negative expression 
at the median.
Statistical analysis
Analyses were performed using SPSS version 20.0.0 (IBM 
SPSS Statistics, IBM Corporation, Armonk, New York, 
United States of America) and graphs were made using 
GraphPad Prism version 5.0 for Windows (GraphPad Soft-
ware, La Jolla, California, United States of America, http://
www.graphpad.com). The Mann–Whitney U test was 
applied for continuous parameters. Correlation analyses 
were performed with Spearman’s rho correlation test. A P 
value < 0.05 was considered statistically significant.
Results
Loss of BAP1‑protein expression is associated 
with an inflammatory phenotype in UM
As expression of UCHL1, a member of the UCH family, 
has been associated with suppression of pro-inflammatory 
cytokines and chemokines in keratinocytes [28], we deter-
mined whether loss of expression of another UCH-mem-
ber, BAP1 might be correlated to the development of an 
inflammatory phenotype in UM. We quantified the number 
of tumor-infiltrating macrophages and T cells by immuno-
fluorescence staining of tissue sections in a cohort of 20 
BAP1-immunopositive tumors and 23 BAP1-immunoneg-
ative tumors from the Leiden cohort, and found that BAP1-
negative tumors contained significantly higher numbers of 
 CD3+ T cells (P = 0.002),  CD8+ T cells (P = 0.003), and 
 CD68+ macrophages (P < 0.001) (Fig. 1a-b).
To corroborate our findings, we analyzed gene expres-
sion array data from 54 cases of UM in which BAP1 
expression as well as chromosome 3 and 8q status had been 
determined. We first correlated potentially-useful probes 
by comparing IF staining data for  CD68+ macrophages, 
 CD3+and  CD8+ T cells with their corresponding CD68, 
CD3, and CD8 probes used for RNA gene expression 
analysis in a group of 24 patients for whom both tests were 
available. The probes with the highest correlation were 
used for further analyses (Table 1), since we assumed that 
these probes represent the corresponding protein expres-
sion most accurately. We subsequently compared the pres-
ence of specific probes with BAP1 expression: a higher 
expression of CD3 (P = 0.016), CD8 (P = 0.015), and CD68 
(P = 0.002) was observed in tumors that did not express 
BAP1 (n = 24) compared to tumors that did express BAP1 
(n = 30; Fig.  1c), corroborating our results obtained with 
IF staining (Fig. 1a, b). These results indicate that loss of 
BAP1 expression in UM is associated with a higher T cell 
and macrophage infiltration.
Since most monosomy 3 tumors lack BAP1 expression, 
it is difficult to determine whether the effects observed 
are due to loss of BAP1 expression or due to loss of one 
chromosome 3. We therefore, focused on atypical cases, 
and observed that within the disomy 3 tumors, loss of 
BAP1 protein expression was associated with increased 
numbers of  CD3+ T cells (P = 0.036),  CD8+ T cells 
(P = 0.018) and  CD68+ macrophages (P = 0.018). Within 
the monosomy 3 tumors, we noticed that the expression 
of BAP1 protein was associated with significantly lower 
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1 3
numbers of  CD3+ T cells (P = 0.034) and  CD8+ T cells 
(P = 0.034), but not of  CD68+ macrophages (P = 0.11; 
Fig. 2a-b). This shows that in disomy 3 as well as mon-
osomy 3 tumors, the loss of BAP1 protein is associated 
with more infiltrating T cells.
In addition, we scrutinized an independent cohort that 
was available from the TCGA for a potential association 
between the BAP1-status and infiltration with T cells and 
macrophages. BAP1-negative tumors showed a higher 
expression of CD3 (P < 0.001) and CD8 (P < 0.001), but 
not for CD68 (P = 0.149) than BAP1-positive tumors 
(Fig. 3), which confirms our finding that loss of BAP1 is 
associated with a higher density of T cells in UM.
Immune cell infiltration of tumors is governed by the 
local production of cytokines and chemokines. We ana-
lyzed whether the expression of several cytokines and 
chemokines involved in T cell and macrophage chemo-
taxis differed between 24 BAP1-positive and 30 BAP1-
negative tumors from the Leiden cohort [31, 32]. Gene 
expression of CCL5 and CXCL10, important chemokines 
in T cell chemotaxis, was higher in the BAP1-negative 
tumors (P < 0.001; P = 0.005 and P = 0.065; Table 2a).
Altogether, these results show that the production of 
immune cell-attracting chemokines and infiltration of dif-
ferent types of immune cells in UM are associated with 
the loss of BAP1 expression, independent of chromosome 
3 loss.
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Fig. 1  Presence of T cells (a), and macrophages (b) as determined by 
IF staining or by gene expression (c) was compared between BAP1-
positive and BAP1-negative tumors from the Leiden cohort
Table 1  Correlation of the values of different probes obtained with 
an Illumina gene expression array with immunohistochemical data in 
the Leiden cohort
The highest correlated probes (in bold) were used for further analysis
P values were obtained by the Spearman’s Rho correlation test
n number of patients, R correlation coefficient
T cell type Probe name Probe number R P value
CD68 (n = 24) CD68 probe 1 ILMN_1714861 0.490 0.015
CD68 probe 2 ILMN_2359907 0.372 0.073
CD68 probe 3 ILMN_2267914 0.252 0.235
CD3 (n = 24) CD3D probe 1 ILMN_2261416 0.760 <0.001
CD3D probe 2 ILMN_2325837 0.748 <0.001
CD3E ILMN_1739794 0.523 0.009
CD3G ILMN_1717197 0.622 0.001
CD8 (n = 24)  CD8A probe 1 ILMN_1768482 0.685 <0.001
CD8A probe 2 ILMN_1760374 0.500 0.013
CD8A probe 3 ILMN_2353732 0.744 <0.001
CD8B probe 1 ILMN_1748601 0.126 0.558
CD8B probe 2 ILMN_2354191 0.388 0.061
Cancer Immunol Immunother 
1 3
Influence of chromosome 8q gain on the inflammatory 
microenvironment
Gain in the copy number of chromosome 8q is considered 
an early event in UM development, occurring before loss 
of chromosome 3 [18, 19]. Seventeen cases of UM from 
Leiden were available in which the tumor showed gain in 
chromosome 8q but did not show loss of chromosome 3 
or lack of BAP1 protein expression. These cases allowed 
us to study the influence of gain of chromosome 8q on 
immune cell infiltration. Tumors that carried additional 
copies of chromosome 8q had an increased expression of 
CD68 (P = 0.006), but not of CD3 and CD8 (Fig. 4). Again, 
using the TCGA data as an independent cohort, we ana-
lyzed whether there was an association between gain of 
chromosome 8q and the presence of macrophages and T 
cells. BAP1-positive tumors with extra copies of 8q had an 
increased expression of CD68 (P < 0.001) (Fig. 3) but not 
of CD3 or CD8 compared to BAP1-positive tumors with a 
normal chromosome 8q. Since these tumors had no loss of 
chromosome 3 or aberrant expression of BAP1, these data 
confirm our finding in the Leiden cohort that the early gain 
in chromosome 8q is responsible for macrophage infiltra-
tion but not for T cell infiltration.
In addition, we determined whether, in the disomy3/
BAP1-positive tumors from the Leiden cohort, extra cop-
ies of chromosome 8q affect the expression of pro-inflam-
matory cytokines. The myeloid-cell attracting chemokines 
CCL3 and CCL2 showed a higher expression in disomy3/
BAP1-positive tumors (P = 0.002 and P = 0.059, respec-
tively) that carried extra copies of chromosome 8q than did 
disomy3/BAP1-positive tumors with two copies of chromo-
some 8q (Table 2b). This was not the case for the expres-
sion of typical T cell attracting chemokines, such as CCL5, 
CXCL12, and CXCL10.
Discussion
We show that the presence of extra copies of chromosome 
8q in UM is associated with macrophage infiltration, while 
loss of BAP1 protein expression, with or without loss of 
chromosome 3, is associated with T cell infiltration in UM.
The chromosomal evolution of aggressive UM is thought 
to start with a mutation in GNAQ/GNA11 [36, 37], fol-
lowed by gain of chromosome 8q that precedes a potential 
loss of one copy of chromosome 3 and/or mutation in the 
BAP1 gene [20, 38]. We show that in UM with disomy 3 
and expression of BAP1, the presence of additional copies 
of chromosome 8q is highly associated with the increased 
expression of macrophage-attracting chemokines and a 
stronger macrophage infiltration. In this subgroup, no effect 
was found with respect to the production of chemokines 
associated with T cell infiltration. This phenomenon could 
not be assessed in monosomy 3 tumors as more than 90% 
of monosomy 3 UM carry extra copies of 8q. Thus, a gain 
in copy number of chromosome 8q is associated with an 
increase in macrophage infiltration.
One might expect that this influx is initiated by acti-
vation of the c-Myc gene, a proto-oncogene located on 
chromosome 8q24, which is upregulated in many types of 
cancer and has been studied in UM [18, 39, 40]. It has pre-
viously been suggested that c-Myc may be involved in the 
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Fig. 2  Comparison of T cells (a) and macrophages (b) as determined 
by IF staining between BAP1-positive and BAP1-negative tumors 
from the Leiden cohort that were either disomic or monosomic for 
chromosome 3 according to the Mann–Whitney U test
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activation of inflammatory mediators in the tumor micro-
environment [41]. However, we previously observed the 
opposite, i.e., an association between a high c-Myc expres-
sion and a low inflammatory phenotype, making it unlikely 
that c-Myc is the relevant factor [42].
Monosomy 3 and loss of BAP1-protein expression are 
strongly correlated in UM, but we observed several atypi-
cal cases which allowed us to separately assess the contri-
bution of chromosome 3 and BAP1-protein expression on 
the magnitude and type of immune cell infiltration and to 
pinpoint that it was the loss of BAP1 which was associated 
with the higher expression of T cell-attracting chemokines 
and a stronger T cell infiltration in UM. The previous stud-
ies have reported that tumor suppressor proteins can be 
involved in the processes and pathways of tumor-promot-
ing inflammation by interacting with transcription factors 
such as nuclear factor-κB (NF-κB) [43]. NF-κB regulates 
genes which are involved in inflammation and immune 
responses. A close family member of BAP1 is UCHL1. 
Similar to BAP1, UCHL1 functions as a tumor suppres-
sor protein [44] and was recently shown to suppress the 
NF-κB pathway, thereby negatively affecting the produc-
tion of type 1 interferon and pro-inflammatory cytokines 
and chemokines, including CCL5 [28]. We, therefore, 
hypothesize that BAP1 may have a similar function as 
UCHL1 and that loss of BAP1 alleviates the suppression 
pathways leading to activation of NF-κB, resulting in the 
production of cytokines and chemokines that attract tumor-
specific T cells into UM.
Obvious correlations between genetic changes and the 
development of an immune infiltrate are not easy to find. 
Loss of function of several tumor suppressor genes (p53, 
PTEN) due to genetic aberrations is known to be associ-
ated with inflammation [45]. Interestingly, loss of BAP1 in 
an unusual cutaneous tumor, the atypical Spitz nevus, was 
associated with a higher presence of T cells [46].
When looking at UM, one of the chemokines that was 
higher in BAP1-negative than BAP1-positive tumors was 
CCL5; another chemokine that was almost significantly 
higher in BAP1-negative tumors was CXCL10. CCL5 and 
CXCL10 play a role in the recruitment of T cells [47]. An 
influence of BAP1 on NF-κB and the additional release 
of pro-inflammatory multifunctional chemokines might 
explain why both macrophages and T cells are found in 
BAP1-negative UM, but this requires further research.
Another chemokine involved in T cell recruitment is 
CXCL12, which is the ligand for chemokine receptor 
CXCR4. Previously, it has been described that CXCR4 is 
Fig. 3  Comparison of T cells 
and macrophages as determined 
by gene expression between 
tumors from the TCGA cohort 
with a normal and abnormal 
chromosome 8q status in cases 
that had low (BAP1-negative) 
or high (BAP1-positive) BAP1 
expression as determined by 
RNA sequencing
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involved in the migration of UM cells to the liver [48, 
49]. In contrast, another group reported that the expres-
sion of CXCR4 was, indeed, correlated with lympho-
cyte infiltration, but had no prognostic relevance in UM 
patients [33]. We observed discrepant results for CXCR4 
in our Leiden cohort, with one probe showing a higher 
expression in BAP1-negative tumors, and another one a 
lower expression (Table 2a).
Previously, it had been shown that tumor-intrinsic 
active β-catenin signaling restrains tumor-infiltration by T 
cells, resulting in the escape of tumors from immune sur-
veillance [50]. The β-catenin protein is encoded by the 
gene CTNNB1, which, like BAP1, is located on chromo-
some 3p21. Hence, loss of chromosome 3 may also reduce 
β-catenin expression. In contrast to BAP1 [24, 25], how-
ever, there is no evidence that the other allele of CTNNB1 
is frequently mutated in UM and thus that the loss of 
Table 2  Expression of pro-inflammatory chemokines and receptors in BAP1-positive and BAP1-negative UM (a), and in disomy 3/BAP1-posi-
tive tumors, with and without 8q gain (b) in the Leiden cohort
The boldface indicates a significant difference
D3 disomy 3, BAP1+ positive BAP1 protein expression, n8q normal chromosome 8q status, 8q gain chromosome 8q gain, n number of patients; 
median (range)
+ P value comparison of chemokine expression in BAP1-positive and BAP1-negative tumors
*P value comparison of chemokine expression in tumors with D3/BAP1+/n8q and tumors with D3/BAP1+/8q gain
(a) BAP1-positive (n = 24) BAP1-negative (n = 30) P  value+
CCL3 (MIP-1α) 6.7 (6.5–8.5) 6.7 (6.3–8.0) 0.321
VEGFA probe 1 6.8 (6.5–7.4) 6.8 (6.5–7.3) 0.651
VEFGA probe 2 6.4 (6.3–6.8) 6.4 (6.2–6.8) 0.403
CXCL12 (SDF-1) probe 1 7.1 (6.6–8.6) 7.3 (6.5–9.4) 0.689
CXCL12 (SDF-1) probe 2 6.6 (6.3–7.1) 6.6 (6.3–7.6) 0.175
CXCL12 (SDF-1) probe 3 6.5 (6.2–7.1) 6.5 (6.0–7.3) 0.848
CCL7 6.2 (6.0–6.5) 6.3 (5.9–6.7) 0.088
CSF-1 6.4 (6.3–6.7) 6.5 (6.3–6.7) 0.130
CCL2 (MCP-1) 7.2 (6.4–9.5) 7.1 (6.4–9.1) 0.614
CCL5 (RANTES) probe 1 6.9 (6.4–10.7) 7.5 (6.5–12.1) <0.001
CCL5 (RANTES) probe 2 7.7 (6.6–12.4) 8.8 (7.0–14.4) 0.005
CXCL10 (IP-10) 6.8 (6.4–10.5) 7.4 (6.4–10.4) 0.065
CCR7 6.4 (6.1–7.0) 6.3 (6.0–7.2) 0.903
CXCR4 probe 1 6.5 (6.2–7.2) 6.7 (6.2–8.3) 0.038
CXCR4 probe 2 6.5 (6.1–6.9) 6.4 (6.2–6.8) 0.010
CXCR4 probe 3 6.6 (6.2–7.5) 6.8 (6.2–8.2) 0.216
(b) D3/BAP1+/n8q (n = 9) D3/BAP1+/8q gain (n = 8) P value*
CCL3 (MIP-1α) 6.6 (6.5–6.8) 6.8 (6.7–8.1) 0.002
VEGFA probe 1 6.7 (6.5–6.9) 6.9 (6.6–7.4) 0.059
VEFGA probe 2 6.4 (6.3–6.6) 6.5 (6.3–6.8) 0.236
CXCL12 (SDF-1) probe 1 7.1 (6.7–7.9) 7.1 (6.6–8.6) 0.743
CXCL12 (SDF-1) probe 2 6.5 (6.3–6.8) 6.5 (6.4–6.8) 0.743
CXCL12 (SDF-1) probe 3 6.5 (6.3–6.7) 6.5 (6.2–7.0) 0.888
CCL7 6.1 (6.0–6.3) 6.3 (6.1–6.4) 0.277
CSF-1 6.4 (6.3–6.6) 6.4 (6.3–6.6) 0.606
CCL2 (MCP-1) 6.8 (6.4–7.7) 7.3 (6.8–9.1) 0.059
CCL5 (RANTES) probe 1 6.8 (6.4–7.0) 6.9 (6.5–7.5) 0.236
CCL5 (RANTES) probe 2 7.4 (6.6–8.2) 7.9 (7.0–8.9) 0.277
CXCL10 (IP-10) 6.7 (6.4–7.4) 6.8 (6.5–8.4) 0.321
CCR7 6.3 (6.1–6.6) 6.4 (6.2–6.7) 0.606
CXCR4 probe 1 6.4 (6.2–6.7) 6.5 (6.3–6.9) 0.114
CXCR4 probe 2 6.5 (6.1–6.6) 6.5 (6.2–6.9) 0.370
CXCR4 probe 3 6.5 (6.2–6.9) 6.6 (6.3–7.3) 0.321
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β-catenin signalling is underlying T cell infiltration in UM. 
In our cohort, we found no correlation between CTNNB1 
expression and the amount of  CD8+ T cells. Furthermore, 
the number of β-catenin-positively staining tumor cells in 
UM is around 10% [51], making its expression an unlikely 
explanation for the absence of T cell infiltration in most 
UM.
Our current findings show that alterations in copy num-
bers or mutations in certain genes can drive a specific 
type of immune response. As the most common treatment 
of UM is irradiation and not enucleation, we wondered 
whether local treatments might affect immune infiltra-
tion in UM. No tumors in either the Leiden cohort or the 
TCGA cohort had received prior irradiation. A previous 
study from our group showed that more T cells were pre-
sent in secondarily enucleated eyes after prior irradiation 
compared to primarily enucleated eyes [52]. As irradiation 
influenced our chromosome testing, we could not always 
analyze the chromosome status in previously irradiated 
tumors [53]. We do not yet know how the type of inflam-
mation or irradiation influences the patient’s response to 
immunotherapy, which at this moment has not been very 
successful in UM.
In conclusion, we provide evidence that the magni-
tude and type of immune cell infiltration observed in the 
subgroup of inflamed UM co-evolve with the sequential 
genetic changes occurring in UM. The initial infiltration 
by macrophages is related to a gain in the copy number of 
chromosome 8q, while additional T cell infiltration is cor-
related to a loss of functional BAP1-protein expression.
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